Shares of Exact Sciences (NASDAQ: EXAS) surged 7.69% in after-hours trading on Monday following the release of its third-quarter 2025 financial results that significantly exceeded analyst expectations. The molecular diagnostics company, known for its Cologuard colorectal cancer test, reported strong revenue growth and a surprise profit, prompting management to raise its full-year guidance.

Exact Sciences reported adjusted earnings per share of $0.24, dramatically beating the consensus estimate of a $0.07 loss. Revenue for the quarter came in at $850.7 million, surpassing the analyst forecast of $810.1 million and representing a 20% increase from the same period last year. The company's screening segment, which includes Cologuard, saw sales reach $2.5 billion, up 20% year-over-year, while precision oncology sales climbed 9% to $710 million.

In light of the strong performance, Exact Sciences raised its 2025 revenue guidance to a range of $3.22 billion to $3.235 billion, up from the previous forecast of $3.13 billion to $3.17 billion. The company also increased its full-year adjusted EBITDA guidance to $470 - $480 million. Kevin Conroy, Chairman and CEO of Exact Sciences, highlighted the continued strength of the Cologuard and Oncotype DX brands, as well as the potential of the new Cancerguard test in development. The positive results and optimistic outlook have fueled investor enthusiasm, driving the stock's significant after-hours gain.